Delek Group’s ADMA Biologics ADMA Stock Holding History

Delek Group’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$132K	Buy	+34,000	New	+$150K	0.01%	217

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Delek Group's ADMA Position: Q2 2019 in Review

Delek Group reduced its ADMA Biologics (ADMA) stake by 47% in Q2 2019, selling an estimated $132K and leaving 34,034 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #218.

Delek Group first reported a position in ADMA in Q3 2018 and has held it in 4 quarters since. The position peaked at $361K in Q3 2018. 67 funds tracked by Wall St. Rank hold ADMA as of Q2 2019.

Delek Group held 34,034 shares of ADMA Biologics worth $129K as of Q2 2019.
Delek Group sold 30,000 ADMA Biologics shares in Q2 2019, an estimated $132K.
ADMA Biologics made up 0.01% of Delek Group's portfolio in Q2 2019, its #218 holding.
Delek Group first reported a position in ADMA Biologics in Q3 2018 and has held it in 4 quarters since.
Delek Group's ADMA Biologics position peaked at $361K in Q3 2018.
67 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.